Propofol for palliative sedation: A systematic review of clinical outcomes, safety, and ethical implications.

In 30 seconds

This systematic review evaluated the use of propofol for palliative sedation in terminally ill patients, analyzing clinical outcomes, safety, and ethical implications. The review included ten non-randomized studies involving 4,072 patients, with symptom control reported in 73%-100% of cases. The findings suggest that propofol may be a viable option in selected cases, though evidence certainty is low to very low.

Key findings

• Symptom control was reported in 73%-100% of cases using propofol.
• Target sedation depth was achieved in 52%-100% of patients.
• Survival time ranged from 19 hours to 38 days.
• Respiratory depression was identified as the main safety concern.

Why it matters

Understanding the role of propofol in palliative sedation is crucial for clinicians managing refractory symptoms in terminally ill patients. The findings highlight both the potential benefits and safety concerns associated with its use.